Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Premier, Inc.’s PINC AI™ Applied Sciences and Datavant Collaborate to Enable Next-Generation Clinical Trials: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc.’s PINC AI™ Applied Sciences and Datavant Collaborate to Enable Next-Generation Clinical Trials


PINC AI™ Applied Sciences (PAS), a division of Premier, Inc. (NASDAQ: PINC), and Datavant, the company that protects, connects and delivers the world’s health data, announce the companies are

Owens & Minor Announces Fourth Quarter 2023 Earnings Release Date and Conference Call: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor Announces Fourth Quarter 2023 Earnings Release Date and Conference Call


Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the fourth quarter of 2023 on Tuesday, February 20, 2024, before trading begins on the New York Stock Exchange.



The Company

Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023.



Fourth Quarter 2023 Financial Highlights:




  • Revenue grew 27%

Agilent Wins Two Scientists’ Choice Awards for Drug Discovery and Development Products:
Agilent Wins Two Scientists’ Choice Awards for Drug Discovery and Development Products


Agilent Technologies Inc. (NYSE: A) announced today that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery &amp

Agilent to Participate in TD Cowen Health Care Conference:
Agilent to Participate in TD Cowen Health Care Conference


Agilent Technologies Inc. (NYSE: A) today announced that CFO Bob McMahon will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference in Boston, Massachusetts, on Monday

Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2023 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2023 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2023 results on Tuesday, February 27, 2024, after the close of the market. Acadia

Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting
Humana Releases Results from Innovative Health Literacy and Healthcare Discrimination Screenings Pilot: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Releases Results from Innovative Health Literacy and Healthcare Discrimination Screenings Pilot


Humana Inc. (NYSE: HUM), a leading U.S. health insurer and healthcare services company, continues to make strides in advancing health equity by releasing the findings of its new pilot study

Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights
Edwards Lifesciences Reports Fourth Quarter Results:
Edwards Lifesciences Reports Fourth Quarter Results


Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.



Highlights and Outlook




  • Q4 sales grew 14 percent to $1.53 billion; constant currency1

Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding
Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding
Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding
Simulations Plus to Participate in Upcoming Healthcare Conferences: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus to Participate in Upcoming Healthcare Conferences


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two

Premier, Inc. Reports Fiscal-Year 2024 Second-Quarter Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2024 Second-Quarter Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2024 second quarter ended December 31, 2023.



"Our

Premier, Inc. Completes Strategic Review Process: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Completes Strategic Review Process


Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-driven healthcare improvement company, today announced that the Company’s Board of Directors has concluded its

LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a

EQS-News: Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard
EQS-News: Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard
EQS-News: Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-Adhoc: Vita 34 publishes preliminary figures on the course of business in 2023
EQS-Adhoc: Vita 34 publishes preliminary figures on the course of business in 2023
EQS-Adhoc: Vita 34 publishes preliminary figures on the course of business in 2023
EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
Inogen to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year

Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology: https://www.flatex.at/fileadmin/dateien_flatex/images/logos/logo-claim_flatex-at_positiv_rgb.png
Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology


Agilent Technologies Inc. (NYSE: A) today announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx)

Simulations Plus Releases GastroPlus® Version 9.9: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Releases GastroPlus® Version 9.9


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the

Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024:
Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024


Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call

EQS-News: MeVis publishes figures for financial year 2022/2023 and forecast for 2023/2024
EQS-News: MeVis publishes figures for financial year 2022/2023 and forecast for 2023/2024
EQS-News: MeVis publishes figures for financial year 2022/2023 and forecast for 2023/2024
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook